News for Blueprint Medicines Stock (BPMC)

Blueprint Medicines (BPMC) Reports Q2 Loss, Tops Revenue Estimates

Zacks Investment Research • 08/01/24

Blueprint Medicines Reports Second Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance

PRNewsWire • 08/01/24

Blueprint Medicines Corporation Investors Are Notified By The Schall Law Firm Of Ongoing Investigations Into Possible Securities Law Breaches

Accesswire • 07/26/24

Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: Should You Buy?

Zacks Investment Research • 07/25/24

Blueprint Medicines Corporation Investors Are Informed By The Schall Law Firm Of Ongoing Investigations Into Possible Securities Law Breaches

Accesswire • 07/19/24

The Schall Law Firm Is Currently Investigating Potential Violations Of Securities Laws For Investors Of Blueprint Medicines Corporation

Accesswire • 07/18/24

Blueprint Medicines to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024

PRNewsWire • 07/18/24

The Schall Law Firm Is Presently Probing Possible Breaches Of Securities Laws For Blueprint Medicines Corporation Investors

Accesswire • 07/17/24

The Schall Law Firm Is At Present Conducting An Inquiry Into Possible Breaches Of Securities Laws For Blueprint Medicines Corporation Investors

Accesswire • 07/13/24

The Schall Law Firm Is Currently Investigating Potential Violations Of Securities Laws For Investors In Blueprint Medicines Corporation

Accesswire • 07/12/24

Currently The Schall Law Firm Is Investigating Potential Violations Of Securities Laws For Shareholders Of Blueprint Medicines Corporation

Accesswire • 07/11/24

At Present The Schall Law Firm Is Probing Possible Breaches Of Securities Laws For Shareholders Of Blueprint Medicines Corporation

Accesswire • 07/10/24

Currently The Schall Law Firm Is Investigating Potential Violations Of Securities Laws For Blueprint Medicines Corporation Shareholders

Accesswire • 07/09/24

The Schall Law Firm Is At Present Probing Possible Breaches Of Securities Laws For Shareholders Of Blueprint Medicines Corporation

Accesswire • 07/08/24

The Schall Law Firm Is Now Probing Possible Infringements Of Securities Laws For Investors Of Blueprint Medicines Corporation

Accesswire • 07/07/24

The Schall Law Firm Is Currently Investigating Potential Violations Of Securities Laws For Stakeholders Of Blueprint Medicines Corporation

Accesswire • 07/06/24

The Schall Law Firm Is Presently Probing Possible Breaches Of Securities Laws For Shareholders Of Blueprint Medicines Corporation

Accesswire • 07/05/24

Potential Securities Law Violations For Shareholders Of Blueprint Medicines Corporation Are Currently Under Investigation By The Schall Law Firm

Accesswire • 07/03/24

The Schall Law Firm Is Currently Probing Potential Securities Law Breaches For Shareholders Of Blueprint Medicines Corporation

Accesswire • 07/02/24

At The Moment The Schall Law Firm Is Scrutinizing Possible Securities Law Violations For Investors of Blueprint Medicines Corporation

Accesswire • 07/01/24

Now The Schall Law Firm Is Looking Into Potential Breaches Of Securities Laws For Stockholders Of Blueprint Medicines Corporation

Accesswire • 06/30/24

At This Time The Schall Law Firm Is Examining Potential Infringements Of Securities Laws For Equity Holders Of Blueprint Medicines Corporation

Accesswire • 06/29/24

Currently The Schall Law Firm Is Investigating Possible Securities Law Breaches For Shareholders Of Blueprint Medicines Corporation

Accesswire • 06/28/24

Currently The Schall Law Firm Is Investigating Possible Violations Of Securities Laws For Shareholders Of Blueprint Medicines Corporation

Accesswire • 06/27/24

At Present The Schall Law Firm Is Probing Potential Securities Law Violations For Stock Owners Of Blueprint Medicines Corporation

Accesswire • 06/26/24